Clinical Trials
Disease | Chronic Plaque Psoriasis |
Title | A comparison between the microbial flora of normal human skin and skin from patients with psoriasis and other inflammatory conditions using broad-range PCR |
Inclusion* | Moderate to severe psoriasis patients who are not currently under treatment (baseline visit) and are eligible to receive either methotrexate or adalimumab (week 12 and 36 visit) |
Study Contact | |
Principal Investigator | Dr. Martin Blaser |
Objective | To evaluate the cutaneous microbial flora. No study agents will be administered in this study. All patients will receive standard of care treatments prescribed by the patient's physician. |
Status | RECRUITING |
Age Requirement | 18-75 years of age |
Gender | males and females |
Disease | Pityriasis Rubra Pilaris |
Title | A comparison between the microbial flora of normal human skin and skin from patients with psoriasis and other inflammatory conditions using broad-range PCR |
Inclusion* | Pityriasis rubra pilaris patients who are not currently under treatment |
Study Contact | |
Principal Investigator | Dr. Martin Blaser |
Objective | To evaluate the cutaneous microbial flora. No study agents will be administered in this study. All patients will receive standard of care treatments prescribed by the patient's physician. |
Status | RECRUITING |
Age Requirement | 18-75 years of age |
Gender | males and females |
Disease | Chronic Plaque Psoriasis |
Title | Phase 2a, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of a new oral medication in subjects with moderate to severe psoriasis |
Inclusion* | Stable moderate to severe chronic plaque psoriasis for at least 6 months |
Study Contact | |
Principal Investigator | Dr. Jerome Shupack |
Objective | To evaluate the safety and efficacy of a new treatment |
Status | RECRUITING |
Age Requirement | 18-80 years of age |
Gender | males and females* |
Disease | Chronic Plaque Psoriasis |
Title | Multi-center, open registry of patients with psoriasis who are candidates for systemic therapies including biologics |
Inclusion* | Patients with all forms of psoriasis receiving systemic therapy |
Study Contact | |
Principal Investigator | Dr. Jerome Shupack |
Objective | Registry study to evaluate the safety and efficacy of systemic treatments for psoriasis. No study agents will be administered in this registry. All patients will receive standard of care treatments prescribed by the patient's physician. |
Status | RECRUITING |
Age Requirement | ≥ 18 years of age |
Gender | males and females |
Disease | Chronic Plaque Psoriasis |
Title | A phase 3, multi-site, randomized, double-blind, placebo-controlled, paralle-group study of the efficacy and safety of 2 doses of a new oral medication in subjects with moderate to severe chronic plaque psoriasis |
Inclusion* | Stable moderate to severe chronic plaque psoriasis for at least 6 months |
Study Contact | |
Principal investigator | Dr. Jerome Shupack |
Objective | To evaluate the safety and efficacy of a new treatment |
Status | Recruitment will start soon |
Age Requirement | ≥ 18 years of age |
Gender | males and females* |
Disease | Chronic Plaque Psoriasis |
Title | A phase 3, multi-site, open-label study of the long term safety and tolerability of 2 oral doses of a new medication in subjects with moderate to severe chronic plaque psoriasis |
Inclusion* | Participation in the above mentioned study |
Study Contact | |
Principal Investigator | Dr. Jerome Shupack |
Objective | To evaluate the long term safety and efficacy of a new treatment |
Status | Recruitment will start soon |
Age Requirement | ≥ 18 years of age |
Gender | males and females* |
Disease | Discoid and Subacute Cutaneous Lupus Erythematosus |
Title | Phase 2, pilot, multicenter, ascending dose study to evaluate the preliminary safety and efficacy of a new oral medication to treat discoid lupus erythematosus and subacute cutaneous lupus erythematosus |
Inclusion* | Men and women, who are 18 years of age or older with a biopsy-proven diagnosis of cutaneous discoid lupus. No evidence of systemic lupus (involvement of internal organs and/or inflammation of blood vessels or joints). |
Study Contact | |
Principal Investigator | Dr. Andrew G. Franks |
Objective | To evaluate the clinical response of discoid lupus patients to an investigational oral medication |
Status | RECRUITING |
Age Requirement | ≥ 18 years of age |
Gender | males and females* |
*: Required for all studies: females of childbearing age must have a negative pregnancy test at screening and agree to use at least two forms of contraception during their participation in the study.
For complete information regarding inclusion and exclusion criteria, please call 212-263-6881 or email bryan.sofen@nyumc.org
